Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 3 minute read Pharma Industry News Can U.S. tariffs on Chinese APIs fast-track Aarti Drugs’ export market growth in 2025? U.S. tariffs on Chinese APIs could benefit Aarti Drugs in 2025. Can Sayakha and Tarapur expansions help it capture regulated-market export growth? byPallavi MadhirajuJuly 19, 2025